Palbociclib: Difference between revisions
New page: <StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''> Palbociclib, sold under the brand name Ibrance among others, is a medication developed ... |
No edit summary |
||
| Line 1: | Line 1: | ||
<StructureSection load=' | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''> | ||
Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. | Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib]. | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||